Literature DB >> 23045283

The RUNX family in breast cancer: relationships with estrogen signaling.

N-O Chimge1, B Frenkel.   

Abstract

The three RUNX family members are lineage specific master regulators, which also have important, context-dependent roles in carcinogenesis as either tumor suppressors or oncogenes. Here we review evidence for such roles in breast cancer (BCa). RUNX1, the predominant RUNX family member in breast epithelial cells, has a tumor suppressor role reflected by many somatic mutations found in primary tumor biopsies. The classical tumor suppressor gene RUNX3 does not consist of such a mutation hot spot, but it too seems to inhibit BCa; it is often inactivated in human BCa tumors and its haploinsufficiency in mice leads to spontaneous BCa development. The tumor suppressor activities of RUNX1 and RUNX3 are mediated in part by antagonism of estrogen signaling, a feature recently attributed to RUNX2 as well. Paradoxically, however RUNX2, a master osteoblast regulator, has been implicated in various aspects of metastasis in general and bone metastasis in particular. Reciprocating the anti-estrogenic tumor suppressor activity of RUNX proteins, inhibition of RUNX2 by estrogens may help explain their context-dependent anti-metastatic roles. Such roles are reserved to non-osseous metastasis, because ERα is associated with increased, not decreased skeletal dissemination of BCa cells. Finally, based on diverse expression patterns in BCa subtypes, the successful use of future RUNX-based therapies will most likely require careful patient selection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23045283      PMCID: PMC5770236          DOI: 10.1038/onc.2012.328

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  191 in total

Review 1.  Regulation mechanisms for the heterodimeric transcription factor, PEBP2/CBF.

Authors:  S C Bae; Y Ito
Journal:  Histol Histopathol       Date:  1999-10       Impact factor: 2.303

2.  Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2.

Authors:  Daniel W Young; Mohammad Q Hassan; Jitesh Pratap; Mario Galindo; Sayyed K Zaidi; Suk-hee Lee; Xiaoqing Yang; Ronglin Xie; Amjad Javed; Jean M Underwood; Paul Furcinitti; Anthony N Imbalzano; Sheldon Penman; Jeffrey A Nickerson; Martin A Montecino; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  Nature       Date:  2007-01-25       Impact factor: 49.962

3.  Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.

Authors:  David P Steensma; Richard J Gibbons; Ruben A Mesa; Ayalew Tefferi; Douglas R Higgs
Journal:  Eur J Haematol       Date:  2005-01       Impact factor: 2.997

4.  Runx2 in normal tissues and cancer cells: A developing story.

Authors:  Karen Blyth; Francois Vaillant; Alma Jenkins; Laura McDonald; Marie Anne Pringle; Camille Huser; Torsten Stein; James Neil; Ewan R Cameron
Journal:  Blood Cells Mol Dis       Date:  2010-06-26       Impact factor: 3.039

5.  Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.

Authors:  Margaretha van der Deen; Jacqueline Akech; David Lapointe; Sneha Gupta; Daniel W Young; Martin A Montecino; Mario Galindo; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

6.  The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.

Authors:  Jitesh Pratap; Amjad Javed; Lucia R Languino; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

7.  RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

Authors:  Wun-Jae Kim; Eun-Jung Kim; Pildu Jeong; Changyi Quan; Jiyeon Kim; Qing-Lin Li; Jeong-Ook Yang; Yoshiaki Ito; Suk-Chul Bae
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

Review 9.  RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Marie-Josée Le Bris; Frédéric Morel; Claude Férec; Marc De Braekeleer
Journal:  Cancer Genet Cytogenet       Date:  2008-08

10.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more
  68 in total

1.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 2.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 3.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 4.  The role of genetics in estrogen responses: a critical piece of an intricate puzzle.

Authors:  Emma H Wall; Sylvia C Hewitt; Laure K Case; Chin-Yo Lin; Kenneth S Korach; Cory Teuscher
Journal:  FASEB J       Date:  2014-09-11       Impact factor: 5.191

5.  Stratified control of IGF-I expression by hypoxia and stress hormones in osteoblasts.

Authors:  Thomas L McCarthy; Zhong Yun; Joseph A Madri; Michael Centrella
Journal:  Gene       Date:  2014-01-15       Impact factor: 3.688

6.  Estrogens and selective estrogen receptor modulators differentially antagonize Runx2 in ST2 mesenchymal progenitor cells.

Authors:  Yonatan Amzaleg; Jie Ji; Donlaporn Kittivanichkul; Anna E Törnqvist; Sara Windahl; Elias Sabag; Aysha B Khalid; Hal Sternberg; Michael West; John A Katzenellenbogen; Susan A Krum; Nyam-Osor Chimge; Dustin E Schones; Yankel Gabet; Claes Ohlsson; Baruch Frenkel
Journal:  J Steroid Biochem Mol Biol       Date:  2018-05-08       Impact factor: 4.292

7.  RUNX3 facilitates growth of Ewing sarcoma cells.

Authors:  Krista L Bledsoe; Meghan E McGee-Lawrence; Emily T Camilleri; Xiaoke Wang; Scott M Riester; Andre J van Wijnen; Andre M Oliveira; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

8.  LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis.

Authors:  H Wu; J Zheng; J Deng; L Zhang; N Li; W Li; F Li; J Lu; Y Zhou
Journal:  Oncogene       Date:  2014-12-08       Impact factor: 9.867

9.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

10.  MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.

Authors:  Gillian Browne; Julie A Dragon; Deli Hong; Terri L Messier; Jonathan A R Gordon; Nicholas H Farina; Joseph R Boyd; Jennifer J VanOudenhove; Andrew W Perez; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Tumour Biol       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.